Suchergebnisse - "Subklewe, Marion"

PubPharm (324)

51

Correction to: CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

52

Correction to: CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

53

TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST

enthalten in: Europäisches Patentamt | 2023

von HAENEL GERULF | KLEIN CHRISTIAN | NEUMANN ANNE-SOPHIE | +1

54

An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA

enthalten in: HemaSphere | 2023

von Rejeski, K. | Greco, R. | Onida, F. | +6

55

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

enthalten in: HemaSphere | 2023

von Rejeski, K. | Blumenberg, V. | Iacoboni, G. | +18

56

Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy

enthalten in: European journal of nuclear medicine and molecular imaging | 2023

von Winkelmann, M. | Blumenberg, V. | Rejeski, K. | +10

57

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

enthalten in: Nature medicine | 2023

von Stein-Thoeringer, C. | Saini, N. | Zamir, E. | +46

CommentIn: Nat Med. 2023 Apr;29(4):785-786. - PMID 36973411

58

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

59

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

60

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13